June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Pilot Data on Monitoring Objective Compliance with Intermittent Occlusion Glasses Therapy
Author Affiliations & Notes
  • Jingyun Wang
    Pennsylvania College of Optometry, Salus University Pennsylvania College of Optometry, Elkins Park, Pennsylvania, United States
    Ophthalmology, Glick Eye Institute, Indianapolis, Indiana, United States
  • Kai Januschowski
    University of Tuebingen, Tuebingen, Germany
    Eye Hospital, Knappschaftsklinikum Sulzbach/Saar, Germany
  • Charlotte Schramm
    University of Tuebingen, Tuebingen, Germany
  • Daniel E Neely
    Ophthalmology, Glick Eye Institute, Indianapolis, Indiana, United States
  • Footnotes
    Commercial Relationships   Jingyun Wang, None; Kai Januschowski, None; Charlotte Schramm, None; Daniel Neely, None
  • Footnotes
    Support  EY026664; Lions Foundation
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2358. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jingyun Wang, Kai Januschowski, Charlotte Schramm, Daniel E Neely; Pilot Data on Monitoring Objective Compliance with Intermittent Occlusion Glasses Therapy. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2358.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Liquid crystal glasses utilize an intermittent occlusion technique (at 30-second opaque/transparent intervals) and avoid adhesive, potentially improving compliance. Several previous studies support the effectiveness of this new occlusion therapy device for amblyopia treatment. However, previous studies had no objective compliance measured for these glasses, which limits understanding of the dose-repsonse for this treatment. This study reports the feasibility and pilot data of a microsensor to monitor objective compliance with intermittent occlusion glasses.

Methods : Six children (3-8 yr) with unilateral amblyopia associated with strabismus and anisometropia were enrolled. Prior to enrollment, they wore glasses for 12 weeks. Amblyopia was defined as an interocular visual acuity difference of at least 0.2 logMAR. At enrollment, depends on severity of amblyopia, they were prescribed 4 or 12 hours of intermittent occlusion therapy glasses (Amblyz™). An inexpensive, commercially availabe waterproof microsensor was attached to the temple arm to monitor complaince with glasses wear for 3 to 4 weeks. Compliance was defined as the percentage of hours of actual glasses wearing compared to the hours of prescribed. Daily compliance was calculated, and general compliance was the average of daily complaince. General compliance at treating days was reported.

Results : Compliance varies among individuals. For instance, Patient A had good general compliance (average 81%), but daily compliance declined to from 110% to 60% over three weeks; Patient B had approximately 52% general compliance, with poor daily compliance on weekends compared with weekdays. General compliance was averaged at 46.4% (ranged from 16% to 81%). Daily compliance declined with time for every patient, and mean daily compliance was fitted by y=66-2*x (day), which indicated a decreasing rate of 2% per day. Neither of the patients’parents reported that the child had discomfort or social concerns related to the attached sensor.

Conclusions : Objective compliance with intermittent occlusion glasses can be monitored with a microsensor. Objective compliance with intermittent occlusion therapy glasses varies among individuals, but on average declines over time course. These preliminary results are limited with short-term follow-up.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×